Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 8;111(14):5153-8.
doi: 10.1073/pnas.1324022111. Epub 2014 Mar 25.

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

Affiliations

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

Andrew J Murphy et al. Proc Natl Acad Sci U S A. .

Abstract

Mice genetically engineered to be humanized for their Ig genes allow for human antibody responses within a mouse background (HumAb mice), providing a valuable platform for the generation of fully human therapeutic antibodies. Unfortunately, existing HumAb mice do not have fully functional immune systems, perhaps because of the manner in which their genetic humanization was carried out. Heretofore, HumAb mice have been generated by disrupting the endogenous mouse Ig genes and simultaneously introducing human Ig transgenes at a different and random location; KO-plus-transgenic humanization. As we describe in the companion paper, we attempted to make mice that more efficiently use human variable region segments in their humoral responses by precisely replacing 6 Mb of mouse Ig heavy and kappa light variable region germ-line gene segments with their human counterparts while leaving the mouse constant regions intact, using a unique in situ humanization approach. We reasoned the introduced human variable region gene segments would function indistinguishably in their new genetic location, whereas the retained mouse constant regions would allow for optimal interactions and selection of the resulting antibodies within the mouse environment. We show that these mice, termed VelocImmune mice because they were generated using VelociGene technology, efficiently produce human:mouse hybrid antibodies (that are rapidly convertible to fully human antibodies) and have fully functional humoral immune systems indistinguishable from those of WT mice. The efficiency of the VelocImmune approach is confirmed by the rapid progression of 10 different fully human antibodies into human clinical trials.

Keywords: antibody generation; immunoglobulin loci.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Several authors are employed by Regeneron Pharmaceuticals, Inc.

Figures

Fig. 1.
Fig. 1.
Sequential modifications leading to three versions of VelocImmune mice. Schematic representation (not to scale) of sequential modifications of the mouse IgH (A) and IgK (B) chain loci with increasing amounts human variable sequences. Double homozygous mice were made from three different stages of heavy and light chain humanization (C).
Fig. 2.
Fig. 2.
B-cell populations in WT and VelocImmune mice. Cells from spleen (A, C, and D) or inguinal lymph node (B) of WT or VelocImmune 1 (V1), 2 (V2), or 3 (V3) mice (column headings) were stained for surface IgM expressing B cells (A and B), surface Ig containing either kappa or lambda light chains (C), or surface IgM of specific allotypes (D); populations are separated by FACS.
Fig. 3.
Fig. 3.
Serum Ig levels. Levels of serum Ig in WT (white bars) or VelocImmune mice (gray bars) for IgM and IgG isotypes (A), as well as IgA (B) and IgE (C).

References

    1. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol. 2008;20(4):450–459. - PubMed
    1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317–327. - PMC - PubMed
    1. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10(5):301–316. - PubMed
    1. Leavy O. Therapeutic antibodies: Past, present and future. Nat Rev Immunol. 2010;10(5):297. - PubMed
    1. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345–352. - PubMed